scholarly journals Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy

2022 ◽  
Author(s):  
Ekaterina Laukhtina ◽  
Fahad Quhal ◽  
Keiichiro Mori ◽  
Reza Sari Motlagh ◽  
Pawel Rajwa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Adjuvant Treatment ◽  
Renal Cell ◽  
Kinase Inhibitors

The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis

2018 ◽  
Vol 14 (9) ◽  
pp. 829-835 ◽  
Author(s):  
Hampig Raphael Kourie ◽  
Ziad Bakouny ◽  
Roland Eid ◽  
Fady GH Haddad ◽  
Joseph Kattan
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Adjuvant Setting
Sign in / Sign up

Export Citation Format

Share Document